摘要
目的：探讨不同药物对婴儿急性上呼吸道感染的疗效和安全性。方法将360例年龄6～12个月的急性上呼吸道感染婴儿随机分为三组，观察组给予口服施保利通片，对照甲组给予口服利巴韦林颗粒，对照乙组给予口服儿童回春颗粒。三组均辅以小儿柴桂退热口服液和物理降温治疗。治疗后动态观察患儿每日体温高峰值，体温恢复正常时间，症状完全消失时间，皮疹发生情况，胃肠道反应，对外周血白细胞的影响以及肝肾功能损害情况。结果施保利通组72 h内每日体温高峰值较儿童回春组和利巴韦林组有明显下降，体温完全恢复正常的时间和症状完全消失的时间均明显缩短，具有统计学意义（ P ＜0．05）。5d后复查血常规，显示施保利通组白细胞总数均在正常范围；儿童回春组有15例白细胞降低，占该组总人数的12．5％，利巴韦林组有30例白细胞明显降低，占该组总人数的25％，具有统计学意义（ P ＜0．05）。结论施保利通治疗婴儿急性上呼吸道感染效果显著，副作用发生率低，安全性好。
Objective To investigate the efficacy and safety of different drugs on infant acute upper re-spiratory tract infection .Methods 360 infants aged 6-12 months with acute upper respiratory tract infection were randomly divided into the observation group treated with Esberitox ,The contrast group A treated with ribavirin granules and the contrast group B treated with rejuvenation .All the three groups were sup-plemented by oral administration of cinnamomum wilsonii gamble and physical cooling treatment .Daily temperature peak value ,body temperature returning to normal ,complete resolution of symptoms ,occur-rence of rash ,gastrointestinal reaction ,the effect on peripheral w hite blood cells and liver and kidney dam-age were observed dynamically .Results The daily temperature peak value ,the time of body temperature re-turning to normal and the complete resolution of symptoms in the observation group decreased significantly more than the contrast group A and the contrast group B （ P〈0 .05） .The routine blood test after 5 days of treatment showed that the total white blood cells were normal ,that the white blood cells decreased in 15 cases（12.5% ） in the contrast group A and that the white blood cells decreased in 30 cases（25% ） in the contrast group B（ P〈0 .05） .Conclusion Esberitox in treating infant acute upper respiratory tract infection can produce curative effect and good security with few side-effects .
出处
《山东医学高等专科学校学报》
2014年第3期237-239,共3页
Journal of Shandong Medical College
关键词
施保利通
婴儿
急性上呼吸道感染
疗效
安全性
Esberitox
Infant
Acute upper respir-atory tract infection
Curative effect
Safety
